Market Size of Differentiated Thyroid Cancer Therapeutics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 21.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Differentiated Thyroid Cancer Therapeutics Market Analysis
The differentiated thyroid cancer (DTC) therapeutics market is expected to register a CAGR of 21.5% during the forecast period. The major factors attributing to the growth of the market are a rise in the incidence of papillary thyroid cancer, which is the most common type of thyroid cancer, accounting for about 80% of all cases. DTC typically doesn't cause any signs or symptoms early in the disease, which results in the development of lumps (nodule) on the neck area, causing difficulties in swallowing, and throat pain, and swollen lymph nodes in the neck.
According to the American Society of Clinical Oncology (ASCO), in 2019, approximately 14,260 men and 37,810 women in the United States were diagnosed with thyroid cancer. It is the most common cancer in women between 20 to 34 years of age, and women are more likely to develop thyroid cancer than men. Furthermore, a rise in government initiatives to control the healthcare burden and growing awareness regarding thyroid cancer treatment options are driving the DTC therapeutics market.